TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← All Stock Lists
▌Top Stocks · MEDICAL DEVICES·Updated October 28, 2026

Top Medical Devices Stocks: Our 3 Picks for October 2026

A three-stock countdown explores medical devices through women’s-health diagnostics, orthopedic implants and robotic surgery, with valuation, profitability and earnings data for each company.

Top Stocks · MEDICAL DEVICESUpdated October 28, 2026
HOLXZBH+1 locked
Last refreshed October 28, 2026·8 min read
Top Medical Devices Stocks: Our 3 Picks for October 2026

Medical devices stocks are caught between a challenged near-term narrative and durable long-term demand. The group has lagged broader healthcare as investors debate whether slower procedure growth, reimbursement pressure and pricing friction are cyclical or structural. Yet valuations have reset enough to make selective opportunities more interesting if execution improves. Abbott’s July 2026 earnings update, which included a higher full-year profit forecast on strength in diagnostics and medical devices, offered a timely reminder that company-specific performance can still overcome sector skepticism.

The structural case rests on aging populations, rising chronic disease prevalence and the shift toward minimally invasive care. Installed bases can also support recurring consumables, software and service revenue. Within the theme, structural heart, electrophysiology, robotics, diabetes devices, diagnostics and select surgical tools offer more compelling growth characteristics than commoditized categories facing heavier margin pressure. That makes product mix, procedure exposure and pricing power important differentiators when comparing companies.

This three-stock countdown focuses on companies with meaningful exposure to medical devices, then considers the business fundamentals supporting that exposure. The selections span women’s-health diagnostics, orthopedic reconstruction, robotic surgery and broader MedTech capabilities. We present the picks in countdown order from #3 to #1, with the strongest overall candidate appearing at the end.

Our screen was limited to US-listed companies with market capitalizations above $500 million and meaningful medical-device exposure. We ranked candidates first by the depth and relevance of that exposure, then by business fundamentals, including revenue and earnings growth, profitability, valuation, earnings consistency and composite quality metrics. The goal is not to treat every healthcare company as a pure-play device business, but to distinguish diversified groups with substantial MedTech operations from narrower or more commoditized exposures. This is a countdown: the best pick is revealed at #1.

3. — Hologic Inc

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

HOLX

Market cap: $17.0B · Quality grade: B+ · Analyst consensus: Hold (avg target $76.67)

What they do. The company develops and supplies women’s-health diagnostics, medical imaging and surgical products through its Diagnostics, Breast Health, GYN Surgical and Skeletal Health segments. Its portfolio includes Aptima assays, ThinPrep cytology, 3D mammography and biopsy systems, MyoSure and NovaSure systems, and Horizon DXA, sold through direct sales, service forces, distributors and representatives.

Why it fits. Hologic is a direct way to access several of the theme’s more defensible niches: diagnostics, breast imaging and minimally invasive gynecological procedures. The combination of assays, imaging equipment and procedure-focused systems gives the company broader women’s-health exposure than a single-product device maker, while its installed diagnostic and imaging base can support continuing clinical usage.

Numbers that matter. Hologic generated $4.1265 billion of revenue and reported a 60.4% gross margin, 22.99% operating margin and 13.18% net margin. Revenue growth was 2.5% year over year, while earnings growth was negative 9.2%, showing that recent expansion has been modest and profitability has faced pressure. Trailing P/E was 31.5394, compared with a forward P/E of 16.835, and TTM EPS was $2.41 versus an estimated next-year EPS of $3.7786. ROE was 10.86% and ROA was 7.43%, supporting a solid but not unambiguously cheap quality profile.

Recent momentum. The latest reported quarter, dated January 29, 2026, missed estimates: EPS was $1.04 versus $1.10 expected, a 5.5% shortfall. That result contrasts with a 6/8 beat rate across the available earnings history. The current analyst consensus is 3.45, with 3 buys and 14 holds; the average target is $76.6667, indicating a largely balanced view rather than broad conviction.

2. ZBH — Zimmer Biomet Holdings Inc

Market cap: $18.6B · Quality grade: A- · Analyst consensus: Hold (avg target $106.90)

What they do. The company designs and sells orthopedic reconstructive products, including knee and hip implants, along with sports medicine, biologics, trauma, foot and ankle, upper-extremity, craniomaxillofacial and thoracic products. It also offers surgical products, bone cement, data and technology, plus ROSA robotic systems and the ZBEdge digital platform to hospitals, surgeons, distributors and healthcare institutions worldwide.

Why it fits. Zimmer Biomet has especially deep exposure to the orthopedic and robotics portions of medical devices. Joint reconstruction provides a direct connection to aging-related procedure demand, while ROSA and ZBEdge add robotic positioning, digital connectivity and data analytics to the implant business. That integrated combination gives the company a clearer technology angle than a purely commodity-oriented orthopedic supplier.

Numbers that matter. Zimmer Biomet generated $8.5088 billion in revenue and produced a 69.5% gross margin, 17.96% operating margin and 9.48% net margin. Revenue rose 4.8% year over year, while earnings growth reached 33.8%, a stronger recent growth profile than the other companies in this countdown. Trailing P/E was 23.6505 and forward P/E was 10.9051; TTM EPS was $4.12 versus an estimated next-year EPS of $9.0533. ROE was 6.41% and ROA was 3.88%, leaving valuation and earnings momentum as the main strengths rather than returns on capital.

Recent momentum. The latest reported quarter, dated August 5, 2026, produced EPS of $2.07 versus $2.01 expected, a 3.0% beat. The available history records a 7/7 beat rate, including a 12.4% surprise in April 2026. Analysts show a 3.5185 consensus with 2 buys and 19 holds; the average target is $106.9048, so the earnings record is stronger than the still-cautious distribution of ratings.

Pick #1Premium members only

Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Methodology

This monthly screen covers US-listed companies with market capitalizations above $500 million and identifiable exposure to medical devices, diagnostics, surgical tools, orthopedics, robotics or related equipment. The ranking gives priority to the depth of theme exposure, then evaluates fundamentals including revenue growth, earnings growth, gross and operating margins, returns on assets and equity, valuation, earnings surprises, analyst consensus and composite quality grade. The article uses the latest available financial and market data supplied for each company; spot prices are excluded from the evergreen data lines because they can age quickly. The list is refreshed monthly as fundamentals, estimates and market conditions change.

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌For Active Investors

Don't trade alone.

Get market intelligence delivered daily.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More stock lists

More to read

All articles
7 Zero Trust Security Stocks Worth Watching in November 2026

7 Zero Trust Security Stocks Worth Watching in November 2026

This countdown spans identity, SASE, endpoint, cloud and network-security businesses across the zero trust security landscape.

Nov 18·13 min
Nordson (NDSN): Semiconductor Growth Meets Valuation Risk
NDSN

Nordson (NDSN): Semiconductor Growth Meets Valuation Risk

Nordson delivered record fiscal Q3 2026 results with double-digit growth in its semiconductor-exposed segment and strong cash generation. The stock earns a Buy, but valuation and leverage keep upside measured.

Nov 18·17 min
Top Healthcare Dividend Stocks: Our 5 Picks for November 2026

Top Healthcare Dividend Stocks: Our 5 Picks for November 2026

Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.

Nov 18·11 min